期刊
CURRENT RHEUMATOLOGY REPORTS
卷 14, 期 6, 页码 516-525出版社
SPRINGER
DOI: 10.1007/s11926-012-0296-9
关键词
Systemic sclerosis; Scleroderma; Vasculopathy; Vasculitis; Angiogenesis; Vasculogenesis; Endothelial cells; ANCA
类别
资金
- United Therapeutics Corp.
- InterMune
- Boehringer Ingelheim
- Actelion Pharmaceuticals Ltd.
- Celgene Corp.
- Sigma-Tau Pharmaceuticals
- Pfizer
- Ergonex Pharma
- Sanofi-Aventis
Systemic sclerosis (SSc) is a devastating and potentially life-threatening multi-organ system disease. SSc is marked by skin thickening and tightening, Raynaud's phenomenon and digital ischemia with ulceration, gastrointestinal dysmotility, cardiopulmonary involvement with pulmonary fibrosis and pulmonary arterial hypertension, as well as renal failure. Fibrosis is the most obvious manifestation of SSc. Vascular involvement and inflammation are other prominent components of SSc pathology, and both features are also seen in vasculitis. This review analyzes whether there is evidence for vasculitis especially with particular organ manifestations and subgroups of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据